The recent 19% decline in aTyr Pharma, Inc.'s stock is likely disappointing for insiders who had invested approximately $911.8k at an average price of $0.91 per share in the past year. As a result of this drop, their investment is now valued at only $442.1k, significantly diminishing their initial stake.
Over the last year, insider Paul Schimmel made the most substantial purchase, acquiring shares worth $912k at $0.94 each. This indicates a belief in the company's potential, especially since the current share price is $0.44. While insider transactions can provide insights, it's essential for investors to exercise caution and not solely rely on these trades when making decisions.
In terms of insider ownership, insiders hold about $1.1m worth of aTyr Pharma stock, representing around 2.5% of the company. While this level of ownership is positive, a higher concentration would be more reassuring. The absence of recent trades by insiders might not be alarming, but investors should remain aware of the broader risks associated with the stock before making investment choices.
In summary, while insider buying can signal confidence in a company's future, the significant stock price drop raises questions about the overall market sentiment. Investors should consider both insider actions and market dynamics to make informed decisions regarding aTyr Pharma.